EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
The Halol facility was placed under Import Alert by USFDA.
The product is backed by required scientific proof and comparative bioequivalence studies
India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Subscribe To Our Newsletter & Stay Updated
